Sunesis Pharma (SNSS) Tops Q3 EPS by 9c

Sunesis Pharma (NASDAQ: SNSS) reported Q3 EPS of ($0.62), $0.09 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $600 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Sunesis Pharma (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Morgan Stanley Upgrades Continental AG (CON:GR) (CTTAY) to Overweight
• Barclays Upgrades Estee Lauder (EL) to Overweight